Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 136

Sort by

Sort Order Select

Journal Articles

The Reason Why We Should Differentiate Monomorphic Epitheliotropic T Cell Lymphoma and Intestinal T Cell Lymphoma, NOS - a Retrospective Study about the Experience of a Single Tertiary Hospital in Korea

Jiyeon Hyeon, Changgon Kim, Sang Eun Yoon, Seok Jin Kim, Young Hyeh Ko, Junhun Cho, Won Seog Kim

Blood (2024) 144 (Supplement 1): 6419.

https://doi.org/10.1182/blood-2024-210911

Published: 2024

Journal Articles

A Phase II Clinical Study for Evaluating the Efficacy and Safety of Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone in Transplantation-Eligible Elderly Patients with Newly Diagnosed Multiple Myeloma (KMM2101)

Sang Eun Yoon, Sung-Hoon Jung, Gyeong Won Lee, Chang-Ki Min, Ja Min Byun, Jae-Yong Kwak, Myung-Won Lee, Ho Sup Lee, Seok Jin Kim, Kihyun Kim

Blood (2024) 144 (Supplement 1): 7045.

https://doi.org/10.1182/blood-2024-198947

Published: 2024

Journal Articles

Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial

Blood (2024) 144 (Supplement 1): 1032.

https://doi.org/10.1182/blood-2024-201533

Published: 2024

Journal Articles

Multicenter, Open-Label, Phase I Study of Azacitidine-CHOP for Patients with Nodal T-Cell Lymphoma with T-Follicular Helper Phenotype

Seok Jin Kim, SangEun Yoon, Ji Hyun Lee, Jeong-Ok Lee, Seong Hyun Jeong, Sung-Nam Lim, Ho-Jin Shin, Duck Hwan Yang, Won Seog Kim

Blood (2024) 144 (Supplement 1): 1683.

https://doi.org/10.1182/blood-2024-205026

Published: 2024

Journal Articles

Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL

Jordan S Goldstein, Mark Roschewski, Won-Seog Kim, Sang Eun Yoon, Seok Jin Kim, Jason R. Westin, Ryan C Lynch, Stefan K. Alig, Sandra Close, Jacob Chabon, Davide Rossi, Wyndham H. Wilson, David Kurtz, Ash A. Alizadeh

Blood (2024) 144 (Supplement 1): 651.

https://doi.org/10.1182/blood-2024-211068

Published: 2024

Journal Articles

Long-Term Outcomes of Bronchus-Associated Lymphoid Tissue Lymphoma Based on Lung Involvement Status: A Single-Center Real-World Data Analysis in Korea

Changgon Kim, Seok Jin Kim, Won Seog Kim, SangEun Yoon

Blood (2024) 144 (Supplement 1): 6309.

https://doi.org/10.1182/blood-2024-206547

Published: 2024

Journal Articles

Gut Microbiome Composition As a Prognostic Marker in CD19-Targeting CAR T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Seok Jin Kim, SangEun Yoon, Woorim Kang, Mauricio Chalita, Hong Hoe Koo, Dong-Wook Hyun, Hyun Kim, Junhun Cho, Won Seog Kim

Blood (2024) 144 (Supplement 1): 1595.

https://doi.org/10.1182/blood-2024-205074

Published: 2024

Journal Articles

Real-World Outcomes of Polatuzumab Vedotin with Bendamustine and Rituximab As Salvage and Bridge Therapy to CAR T-Cell Treatment in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Changgon Kim, SangEun Yoon, Hyun-Young Kim, Duck Cho, Hong Hoe Koo, Junhun Cho, Won Seog Kim, Seok Jin Kim

Blood (2024) 144 (Supplement 1): 3107.

https://doi.org/10.1182/blood-2024-204987

Published: 2024

Journal Articles

CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis

Jinchul Kim, Jinhyun Cho, Moon Hee Lee, Sang Eun Yoon, Won Seog Kim, Seok Jin Kim

Blood (2024) 144 (6): 629–638.

https://doi.org/10.1182/blood.2023023419

Published: 2024

Includes: Supplemental data

Journal Articles

Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy

Jordan Goldstein, Won Seog Kim, Sang Eun Yoon, Seok Jin Kim, Mark Roschewski, Jason Westin, Ryan C Lynch, Stefan K. Alig, Sandra Close, Jacob J. Chabon, Davide Rossi, Wyndham H Wilson, Maximilian Diehn, Ash A. Alizadeh, David M. Kurtz

Blood (2023) 142 (Supplement 1): 187.

https://doi.org/10.1182/blood-2023-187759

Published: 2023

Journal Articles

Nivolumab in Relapsed or Refractory Primary CNS Lymphoma: Multicenter, Retrospective Study

Jun Ho Yi, Seok Jin Kim, Sang A Kim, Jongheon Jung, Dok Hyun Yoon

Blood (2023) 142 (Supplement 1): 1772.

https://doi.org/10.1182/blood-2023-186554

Published: 2023

Journal Articles

Phase II Study of Lenalidomide Maintenance after Salvage Therapy for Relapsed or Refractory Peripheral T-Cell Lymphomas

Seok Jin Kim, Myung-Won Lee, Sung-Nam Lim, Ka-Won Kang, Sang Eun Yoon, Yoo Jin Lee, Hye Jin Kang, Ho Sup Lee, Hyo Jung Kim, Hong Hoe Koo, Ho-Jin Shin, Hyeon-Seok Eom, Jong-Ho Won, Won Seog Kim

Blood (2023) 142 (Supplement 1): 3073.

https://doi.org/10.1182/blood-2023-181809

Published: 2023

Journal Articles

Treatment of Relapsed/Refractory Hgbcl and Bukitt's Lymphoma with c-Myc Rearrangement: A Multi-Center, Open-Label, Phase 2 Study of PC-002 (SepB), a First-in-Class Deubiquitinase Inhibitor Inducing Myc Degradation

Blood (2023) 142 (Supplement 1): 1754.

https://doi.org/10.1182/blood-2023-190995

Published: 2023

Journal Articles

Prognostic Utility of Minimal Residual Disease (MRD) after Curative Intent Induction Therapy for DLBCL: A Prospective Real-World Ctdna Study

Brian J. Sworder, Sang Eun Yoon, Seok Jin Kim, Andre Schultz, Gregory Hogan, Sandra Close, Jacob J. Chabon, Maximilian Diehn, David M. Kurtz, Ash A. Alizadeh, Won Seog Kim

Blood (2023) 142 (Supplement 1): 69.

https://doi.org/10.1182/blood-2023-187650

Published: 2023

Journal Articles

Personal Financial Burdens of Multiple Myeloma: A Deep Dive into the Patient's Journey Using Qualitative Interview

YoungJu PARK, Juhee Cho, Sooyeon Kim, Kihyun Kim, Sang Eun Yoon, Danbee Kang, Garam Bang, Nayeon Kim, Jeong Hyun Park, Seok Jin Kim

Blood (2023) 142 (Supplement 1): 5088.

https://doi.org/10.1182/blood-2023-178418

Published: 2023

Journal Articles

A Novel PI3K γ/δ and DNA-PK Triple Inhibitor, BR101801, for r/r PTCL: A Phase 1a/b, Multi-Center, Open-Label Clinical Trial

Bong-Seog Kim, Seok Jin Kim, Dok Hyun Yoon, Jin Seok Kim, Tae Min Kim, Eunyoung Lee, Jeong-Ok Lee, Deok-Hwan Yang, Won-Sik Lee

Blood (2023) 142 (Supplement 1): 1701.

https://doi.org/10.1182/blood-2023-173010

Published: 2023

Journal Articles

Isatuximab and Cemiplimab in Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma: A Multi-Center, Open-Labeled Phase II Study (CISL2102/ICING study)

Seok Jin Kim, Sang Eun Yoon, Deok-Hwan Yang, Sung Yong Oh, Yoon Seok Choi, Seong Hyun Jeong, Min Kyoung Kim, Sung-Nam Lim, Junhun Cho, Won Seog Kim

Blood (2023) 142 (Supplement 1): 301.

https://doi.org/10.1182/blood-2023-174476

Published: 2023

Journal Articles

Real-World Data of Outcome of Patients with Newly Diagnosed Bronchial-Associated Lymphoid Tissue Lymphoma: A Multi-Center Retrospective Analysis with Long-Term Survivors

Kunye Kwak, Yong Park, Byung Soo Kim, Sang Eun Yoon, Won Seog Kim, Kwai Han Yoo, Ka-Won Kang, Seok Jin Kim

Blood (2023) 142 (Supplement 1): 6143.

https://doi.org/10.1182/blood-2023-188254

Published: 2023

Journal Articles

Diverse Microbiome Characteristics in Treatment Naïve Extranodal NK/T-Cell Lymphoma Patients

Sang Eun Yoon, Woorim Kang, Junhun Cho, Jiyeon Hyeon, Seok Jin Kim, Won Seog Kim

Blood (2023) 142 (Supplement 1): 5728.

https://doi.org/10.1182/blood-2023-173788

Published: 2023

Journal Articles

The influence of microbial dysbiosis on immunochemotherapy-related efficacy and safety in diffuse large B-cell lymphoma

Sang Eun Yoon, Woorim Kang, Seunghyun Choi, Yoon Park, Mauricio Chalita, Hyun Kim, Je Hee Lee, Dong-Wook Hyun, Kyung Ju Ryu, Hojun Sung, Jae-Yun Lee, Jin-Woo Bae, Won Seog Kim, Seok Jin Kim

Blood (2023) 141 (18): 2224–2238.

https://doi.org/10.1182/blood.2022018831

Published: 2023

Includes: Supplemental data

NARROW

The Reason Why We Should Differentiate Monomorphic Epitheliotropic T Cell Lymphoma and Intestinal T Cell Lymphoma, NOS - a Retrospective Study about the Experience of a Single Tertiary Hospital in Korea

A Phase II Clinical Study for Evaluating the Efficacy and Safety of Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone in Transplantation-Eligible Elderly Patients with Newly Diagnosed Multiple Myeloma (KMM2101)

Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial

Multicenter, Open-Label, Phase I Study of Azacitidine-CHOP for Patients with Nodal T-Cell Lymphoma with T-Follicular Helper Phenotype

Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL

Long-Term Outcomes of Bronchus-Associated Lymphoid Tissue Lymphoma Based on Lung Involvement Status: A Single-Center Real-World Data Analysis in Korea

Gut Microbiome Composition As a Prognostic Marker in CD19-Targeting CAR T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Real-World Outcomes of Polatuzumab Vedotin with Bendamustine and Rituximab As Salvage and Bridge Therapy to CAR T-Cell Treatment in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis

Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy

Nivolumab in Relapsed or Refractory Primary CNS Lymphoma: Multicenter, Retrospective Study

Phase II Study of Lenalidomide Maintenance after Salvage Therapy for Relapsed or Refractory Peripheral T-Cell Lymphomas

Treatment of Relapsed/Refractory Hgbcl and Bukitt's Lymphoma with c-Myc Rearrangement: A Multi-Center, Open-Label, Phase 2 Study of PC-002 (SepB), a First-in-Class Deubiquitinase Inhibitor Inducing Myc Degradation

Prognostic Utility of Minimal Residual Disease (MRD) after Curative Intent Induction Therapy for DLBCL: A Prospective Real-World Ctdna Study

Personal Financial Burdens of Multiple Myeloma: A Deep Dive into the Patient's Journey Using Qualitative Interview

A Novel PI3K γ/δ and DNA-PK Triple Inhibitor, BR101801, for r/r PTCL: A Phase 1a/b, Multi-Center, Open-Label Clinical Trial

Isatuximab and Cemiplimab in Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma: A Multi-Center, Open-Labeled Phase II Study (CISL2102/ICING study)

Real-World Data of Outcome of Patients with Newly Diagnosed Bronchial-Associated Lymphoid Tissue Lymphoma: A Multi-Center Retrospective Analysis with Long-Term Survivors

Diverse Microbiome Characteristics in Treatment Naïve Extranodal NK/T-Cell Lymphoma Patients

The influence of microbial dysbiosis on immunochemotherapy-related efficacy and safety in diffuse large B-cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only